



Molecular Biology of Sarcomas



Naima Azouzi, Kjetil Boye, Birgitte Bjørnerud, Marie K. Gillstrøm, Ellen M. Haugsten, Michal Kostas, Leonardo A. Meza-Zepeda, Else Munthe, Anine Ottestad, Andrea Terrasi, Jørgen Wesche



Aims

We aim to reveal new oncogenic mechanisms in sarcomas. Genomic and proteomic screens in sarcoma clinical samples and models lay the basis for the discovery of cancer cell programs that can be targetable, and novel biomarkers

Hyperactive signalling in sarcomas



Projects

Osteosarcoma


Pi-induced activation of FGFR1

- novel activation mechanism of FGFR1 based on kinase oxidation

Liposarcoma

Clinical trial (PERELI)

- combination of FGFR inhibitor and PD-1 inhibition



Rhabdomyosarcoma

CRISPR screen in FGFR4-driven RMS

Cell migration and invasion

GIST

Prognostic biomarker (GIST-Risk)

Tumour heterogeneity (GIST-Spatial)

Drug resistance (GIST-Resist)